StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Equities research analysts at StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently weighed in on the company. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Jefferies Financial Group restated a “hold” rating and issued a $0.50 price target (down previously from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Finally, Royal Bank of Canada decreased their price target on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, eight have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Stock Performance

MRNS opened at $0.55 on Friday. The firm has a 50 day moving average price of $0.46 and a 200 day moving average price of $0.88. The company has a market cap of $30.32 million, a PE ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 1 year low of $0.22 and a 1 year high of $10.50.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in MRNS. AQR Capital Management LLC lifted its stake in Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 12,934 shares during the last quarter. World Investment Advisors LLC bought a new position in Marinus Pharmaceuticals during the third quarter worth $104,000. Virtu Financial LLC bought a new position in Marinus Pharmaceuticals during the fourth quarter worth $36,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in Marinus Pharmaceuticals during the fourth quarter worth $54,000. Finally, Jacobs Levy Equity Management Inc. lifted its stake in Marinus Pharmaceuticals by 39.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 117,255 shares during the last quarter. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.